These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 24080883)

  • 21. [New triple therapy in chronic hepatitis C. Increased patient chances].
    Stiefelhagen P
    MMW Fortschr Med; 2011 Sep; 153(39):20. PubMed ID: 21991830
    [No Abstract]   [Full Text] [Related]  

  • 22. [Boceprevir and telaprevir: clinical efficacy, safety and drug-drug interactions].
    Nikitin AV
    Antibiot Khimioter; 2012; 57(9-10):47-9. PubMed ID: 23477220
    [No Abstract]   [Full Text] [Related]  

  • 23. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.
    Butt AA; Kanwal F
    Clin Infect Dis; 2012 Jan; 54(1):96-104. PubMed ID: 22156853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protease inhibitors for treatment of genotype 1 hepatitis C virus infection.
    Rowe IA; Mutimer DJ
    BMJ; 2011 Nov; 343():d6972. PubMed ID: 22074942
    [No Abstract]   [Full Text] [Related]  

  • 25. New hepatitis C regimen stimulates changes in therapy management.
    Reinke T
    Manag Care; 2011 Dec; 20(12):41-2. PubMed ID: 22259876
    [No Abstract]   [Full Text] [Related]  

  • 26. Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection.
    Trembling PM; Tanwar S; Dusheiko GM
    Expert Rev Anti Infect Ther; 2012 Mar; 10(3):269-79. PubMed ID: 22397560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triple therapy for hepatitis C.
    Giordano C
    JAAPA; 2012 Feb; 25(2):59-60. PubMed ID: 22416558
    [No Abstract]   [Full Text] [Related]  

  • 28. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.
    Jacobson IM; Pawlotsky JM; Afdhal NH; Dusheiko GM; Forns X; Jensen DM; Poordad F; Schulz J
    J Viral Hepat; 2012 May; 19 Suppl 2():1-26. PubMed ID: 22404758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Telaprevir: hope on the horizon, getting closer.
    Weisberg IS; Jacobson IM
    Clin Liver Dis; 2009 Aug; 13(3):441-52. PubMed ID: 19628160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 3 study results released for telaprevir and HCV.
    AIDS Patient Care STDS; 2010 Oct; 24(10):685-6. PubMed ID: 20945535
    [No Abstract]   [Full Text] [Related]  

  • 31. Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.
    Belperio PS; Hwang EW; Thomas IC; Mole LA; Cheung RC; Backus LI
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1021-7. PubMed ID: 23524130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Telaprevir and boceprevir: a potential role for therapeutic drug monitoring.
    Dolton MJ; Ray JE; McLachlan AJ
    Ther Drug Monit; 2013 Jun; 35(3):414-5. PubMed ID: 23670484
    [No Abstract]   [Full Text] [Related]  

  • 33. Future perspectives: towards interferon-free regimens for HCV.
    Gane E
    Antivir Ther; 2012; 17(6 Pt B):1201-10. PubMed ID: 23186654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy of triple therapy in patients with chronic hepatitis C not treated and patients previously treated ineffectively].
    Kozielewicz D; Halota W; Dybowska D
    Przegl Epidemiol; 2012; 66(1):49-54. PubMed ID: 22708298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Telaprevir: new possibilities for antiviral treatment in patients with chronic hepatitis C].
    Nikitin IG; Gogova LM; Baikova IE; Kislyakov VA; Volynkina VM
    Ter Arkh; 2012; 84(11):75-80. PubMed ID: 23252254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HCV protease inhibitors bring new options for patients.
    Traynor K
    Am J Health Syst Pharm; 2011 Aug; 68(15):1372, 1374, 1379. PubMed ID: 21785015
    [No Abstract]   [Full Text] [Related]  

  • 37. [Studies with boceprevir].
    MMW Fortschr Med; 2011 Jul; 153(29-31):16. PubMed ID: 21830728
    [No Abstract]   [Full Text] [Related]  

  • 38. Update of the Belgian Association for the Study of the Liver guidelines for the treatment of chronic hepatitis C genotype 1 with protease inhibitors.
    Orlent H; Deltenre P; Francque S; Laleman W; Moreno C; Bourgeois S; Colle I; Delwaide J; De Maeght S; Mulkay JP; Stärkel P; Reynaert H;
    Acta Gastroenterol Belg; 2012 Jun; 75(2):245-59. PubMed ID: 22870791
    [No Abstract]   [Full Text] [Related]  

  • 39. A major advance in treating hepatitis C.
    Johns Hopkins Med Lett Health After 50; 2011 Dec; 23(10):6. PubMed ID: 22216468
    [No Abstract]   [Full Text] [Related]  

  • 40. New HCV drugs trigger race for more tolerable therapies.
    Williams SC
    Nat Med; 2011 Dec; 17(12):1526. PubMed ID: 22146431
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.